NB
TEVA icon

NBT Bank’s Teva Pharmaceuticals TEVA Stock Holding History

NBT Bank’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4
Closed -$88 – 837
2024
Q4 		$88 Hold
4
– – ﹤0.01% 768
2024
Q3 		$72 Buy
+4
New +$70 ﹤0.01% 819
2016
Q1 		– Sell
-3,256
Closed -$213K – 205
2015
Q4 		$213K Buy
+3,256
New +$201K 0.04% 185
2015
Q2 		– Sell
-3,462
Closed -$215K – 202
2015
Q1 		$215K Sell
3,462
-188
-5% -$10.9K 0.03% 191
2014
Q4 		$210K Sell
3,650
-170
-4% -$9.47K 0.03% 196
2014
Q3 		$206K Sell
3,820
-290
-7% -$15.4K 0.03% 193
2014
Q2 		$215K Sell
4,110
-1,072
-21% -$54.8K 0.03% 195
2014
Q1 		$274K Sell
5,182
-1,930
-27% -$89.2K 0.04% 183
2013
Q4 		$285K Sell
7,112
-1,387
-16% -$54.6K 0.04% 183
2013
Q3 		$321K Sell
8,499
-637
-7% -$24.8K 0.05% 169
2013
Q2 		$359K Buy
+9,136
New +$356K 0.05% 161

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

NBT Bank's TEVA Position: Q1 2025 in Review

NBT Bank sold out of Teva Pharmaceuticals (TEVA) in Q1 2025, closing a stake of 4 shares — an estimated $88 sold.

NBT Bank first reported a position in TEVA in Q2 2013 and held it in 11 quarters. The position peaked at $359K in Q2 2013. 560 funds tracked by Wall St. Rank hold TEVA as of Q1 2025.

  • NBT Bank reported no remaining Teva Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • NBT Bank sold 4 Teva Pharmaceuticals shares in Q1 2025, an estimated $88.
  • NBT Bank first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 11 quarters.
  • NBT Bank's Teva Pharmaceuticals position peaked at $359K in Q2 2013.
  • 560 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2025.

Based on NBT Bank's 13F filing for Q1 2025, filed 17 Apr 2025.